Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

10 September 2024

A new report from the Access to Medicine Foundation reveals how patient-focused pharma companies' access efforts are

Morningstar covers the Access to Medicine Foundation’s latest report on the critical issue of how some of the largest pharma companies are reaching patients worldwide, especially in low- and middle-income countries (LMICs)

The article details the Access to Medicine Foundation's latest report, which evaluates the patient reach commitments and measurement methods of major pharmaceutical companies.

The article outlines the report's findings, which identified 42 unique approaches for measuring patient reach. Notably,19 of the 20 assessed companies reported using approaches to track the patients they reach with essential medicines in low- and middle-income countries (LMICs). It also highlights the potential for companies to refine their commitments and improve their efforts to assist those in need.

“We have seen that the pharmaceutical industry is making ambitious commitments to reach more patients worldwide,” the article quotes Jayasree K. Iyer, CEO of the Foundation. “However, this report reveals that there is still much work to be done in achieving meaningful impact and calls for urgent steps to ensure lifesaving products reach every patient, everywhere.”                   

NOW ONLINE

Foundation's new report reveals what pharma companies can do to ensure their products reach underserved populations

Read more

News

Read the latest news at the Foundation
News

More superbugs, fewer drugs. How can pharma companies ensure the handful of promising antimicrobials make it to the frontlines of drug resistance?

23 May 2024
Featured News

2024 Amsterdam Session identifies strategies to accelerate expansion of diabetes care in LMICs

07 May 2024

Divya Verma

Head of Communications

dverma@accesstomedicinefoundation.org

Get in touch

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved